CompletedPhase 2

Efficacy of Ultrasound Contrast Agent to Assess Renal Masses

Canada167 participantsStarted 2009-10

Plain-language summary

Patients with an incidentally discovered small renal masses (SRM) \< 4 cm in diameter are included. All patients will undergo biopsy for tissue diagnosis. Most patients will be followed by imaging. Study intervention includes low MI US to be performed following both bolus and infusion injection of Definity contrast. Presence and absence of vascularity, pattern of vascularity, and TIC values will be correlated with the final pathology to find features differentiating benign from malignant masses.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with newly diagnosed Renal mass \< 4 cmm, who are going to undergo diagnostic CT, MRI or biopsy.

What they're measuring

biopsy

Timeframe: 12 to 18 months

Trial details

NCT IDNCT01062178

SponsorUniversity Health Network, Toronto

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-10

View on ClinicalTrials.gov More Renal Cell Carcinoma trials